	US 12,247,229 B2
	Bacteriophage and therapeutic agent for bacterial endophthalmitis
Ken Fukuda, Kochi (JP); Shigenobu Matsuzaki, Kochi (JP); Atsuki Fukushima, Kochi (JP); Masanori Daibata, Kochi (JP); and Jumpei Uchiyama, Kanagawa (JP)
Assigned to NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY, Kochi (JP)
Filed by NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY, Kochi (JP)
Filed on Sep. 8, 2023, as Appl. No. 18/463,731.
Application 18/463,731 is a division of application No. 16/979,371, abandoned, previously published as PCT/JP2019/009112, filed on Mar. 7, 2019.
Claims priority of application No. 2018-044407 (JP), filed on Mar. 12, 2018.
Prior Publication US 2024/0026308 A1, Jan. 25, 2024
Int. Cl. C12N 7/00 (2006.01); A61K 35/76 (2015.01); A61P 31/04 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 35/76 (2013.01); A61P 31/04 (2018.01); C12N 2795/10121 (2013.01); C12N 2795/10132 (2013.01)]

3 Claims

1. A method for treating bacterial endophthalmitis comprising the step of administrating one or more bacteriophages selected from the group consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887) and Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), wherein the one or more bacteriophages are in a therapeutic composition.